β‐Blocker Therapy Prior to Admission for Acute Coronary Syndrome in Patients Without Heart Failure or Left Ventricular Dysfunction Improves In‐Hospital and 12‐Month Outcome: Results From the GULF‐RACE 2 (Gulf Registry of Acute Coronary Events‐2)
Key result
In a cohort of 7,407 ACS patients without heart failure, beta-blocker therapy was associated with reduced in-hospital and 12-month mortality compared to the non-beta-blocker group.
Why the study?
Does beta-blocker therapy reduce in-hospital and 12-month mortality in acute coronary syndrome patients without heart failure or left ventricular dysfunction?
Population
7,407 patients hospitalized for acute coronary syndrome without heart failure. A subgroup of 4,208 patients…
Comparison
Beta-blocker therapy prior to admission for… vs No beta-blocker therapy prior to admission or at…
Design
Cohort
Follow-up
12 months
Authors
Discussion
Loading...
Member takes
Implication
May support beta-blocker use in ACS without HF; leaves open need for RCTs to confirm benefit.
Study Design
Type
Cohort (n=7,903)
Multicenter
Yes
Structured PICO
Does beta-blocker therapy reduce in-hospital and 12-month mortality in acute coronary syndrome patients without heart failure or left ventricular dysfunction?
P
Population
7,903 patients hospitalized for acute coronary syndrome, including 7,407 without heart failure, followed for up to 12 months to assess the impact of beta-blocker therapy.
E
Exposure
Beta-blocker therapy prior to admission for acute coronary syndrome, and continued prescription on discharge.
C
Comparator
No beta-blocker therapy prior to admission or at discharge.
O
Outcome
In-hospital mortality and 12-month mortality.hard clinical
Beta-blocker therapy prior to admission and at discharge is associated with reduced in-hospital and 1-year mortality in acute coronary syndrome patients without heart failure or left ventricular dysfunction.
Cite This Study
Khalil et al. (2017) conducted a cohort in Acute Coronary Syndrome without Heart Failure (n=7,903). β-blocker therapy vs. No β-blocker therapy was evaluated on In-hospital mortality and 12-month mortality. In a cohort of 7,407 ACS patients without heart failure, beta-blocker therapy was associated with reduced in-hospital and 12-month mortality compared to the non-beta-blocker group.